Biotech stopped building molecules. It started rebuilding teams.

The 2026 biotech industry has stopped building molecules and started rebuilding teams. Call it the relaunch chassis: a proven executive team sells a drug to Big Pharma, then reappears inside a US-listed shell with a China-licensed asset and a 'company creator' sponsor that finances the wrapper as a product. The team, the sponsor, the asset, and the wrapper are all separate pieces, swappable on their own. The locked input is the operating team.

According to STAT+, Akero's MASH drug exited to Novo Nordisk for $5 billion; Andrew Cheng, Kitty Yale, and William White are back as Avere Therapeutics within a year, with a $320M PIPE from Fairmount and Hansoh, a reverse merger into NextCure (Nasdaq: AVRX), and an oral IL-23 peptide aimed at psoriasis and ulcerative colitis. The naïve read is a comeback story. The actual read is a template.

The mechanism generalizes. A same-day AstraZeneca deal with Dizal for an EGFR inhibitor confirms Chinese-origin assets are now a routine Western input. Public investors are buying an operating team in a new ticker, not new science. Whoever controls the chassis — the team, the sponsor, the listing route — captures the spread between Chinese development costs and US biotech multiples. The molecule is the excuse. The chassis is the business.